In the first half of the twenty-first century, U.S. psychiatrists are prescribing the second generation neuroleptics—Zyprexa, Risperdal, Geodon, Seroquel, Abilfy—to coerce innocent children and the elderly into submission.
Sen. Grassley obtained documents confirming NAMI as a front group for pharma companies who underwrite ¾ of NAMI donations—in 2006 to 2008 that was a hefty $23 million.
It is difficult to comprehend, why the Obama administration, which has made cost-cutting a legislative centerpiece of healthcare reform, would remove the most potent, financial penalty in its existing legal arsenal from its settlement with Pfizer.
Pfizer, the world’s largest drug manufacturer has the dubious distinction of being a corporate "repeat offender…"
Two high ranking FDA officials’ conflicts of interest have led one to resign, the other is under investigation by the Inspector General of the Department of Health and Human Services:
At the July 30, 2009 FDA advisory committee hearing, the only formal presentations at the meeting were a summary of the safety and efficacy data by the sponsor.
Today’s New York Times reports (below) that "court documents provide a paper trail showing that Wyeth contracted with a medical communications company to outline articles, draft them and then solicit top physicians to sign their names, even though many of the doctors contributed little or no writing."
“I was trained from day one to market the drug illegally…My job was to promote Neurontin and motivate doctors to experiment on patients. After being hired as a medical liaison, I was selling drugs. The uses promoted were from the “snake-oil list” of 13 medical conditions."
Unless the overall treatment and services provided to schizophrenia patients in Finland is unique and especially protective—which the authors do not suggest—their claimed findings of lowered mortality rates for antipsychotic drug users are belied by a consistent body of evidence.
Among the most damaging scientific evidence against the use of antipsychotic drugs is empirical evidence that they cause brain damage.
The FDA’s expanded marketing approval process for antipsychotics, highly toxic drugs, is unaffected by evidence uncovered by the US Justice Department showing that the studies submitted by drug manufacturers were often flawed, if not fraudulent.
"The story’s pretty clear, and pretty embarrassing for the profession of psychiatry, which has allowed itself to be led by marketing," says Dr. Robert Rosenheck, Yale.
